Yes, it won't be long before a placing news |
Certainly getting well bought this week. Small sells generally mopped up by bigger buys.It won't be long before we get some news. |
Even an AI robot would have made a few bobs by now |
When will these guys gonna sell some kits instead of begging for funds? |
Snowflake! |
Another day without sale news |
Yes but when can investors expect some sales? Or is it not going to happen? |
genedrive plc
@genedriveplc
We are all set up and ready to welcome you to Medlab Middle East!
Visit stand Z2.K11 to discover our innovative pharmacogenetic testing products. |
Looks like a 1-2 (1-2) to me. Still maintain a 10p short term target on these. |
Let the company do the talking.
When are their products expected to sell?
What? No sales and no revenue!!! |
It's half 10 at night, you are posting on a share thread where you have no position |
This could drop 30-40% on a placing news |
Share is on backwards momentum.
Company has no cash. |
#desperate
#buysignal |
Still no FDA news?
And no sales?
How many more years will it take? |
When can investors expect sales?
Becoz it's no good if the kits can't sell |
This dog share couldn't break 2.3p with massive placing looming |
A school kid would have made some instant profit selling lemonade. GDR asva company hasn't made a penny |
How much money is GDR making?
£0? Nevermind |
So the Middle East is rather relevant I think, as cited in post 937. |
Through detailed examination of previous NICE reports, I did indeed find reference to ethnic breakdown relevance.
One of several points by Nicky J. WeltonOrcid, University of Bristol, Bristol, UK
Joe Carroll, University of Bristol, Bristol, UK in a peer review.
' It would be better for the authors to look at the LOF rates in the UK population that uses the NHS based on its current ethnic breakdown rather than to focus on those of European ancestry alone. More so considering the LOF rates are higher in non-European populations.
Part of the issue with dipryridamole as an alternative is that it is poorly tolerated compared to aspirin and clopidogrel. Is there data available about the rates of discontinuation of dipyridamole within stroke patients? Could that information be incorporated into your models?' |
Hey!
The Middle East!
'In just 1 WEEK, Genedrive are exhibiting at MedlabMiddle East!
Visit stand Z2.K11 to discover our innovative pharmacogenetic testing products.
Contact enquiries@genedrive.com to book a meeting.' |
'In just 1 WEEK, Genedrive are exhibiting at MedlabMiddle East!
That translates to no sales, so they go there in hope someone will buy their goods |
'Background: People who have experienced a stroke are at high risk of recurrent strokes. Clopidogrel is prescribed to people who have had a non-cardioembolic stroke. There is evidence that clopidogrel is not effective for patients with CYP2C19 loss-of-function alleles. Pharmacogenetic testing is a potential strategy to identify such patients and guide prescription of appropriate antiplatelet treatment. This study aimed to provide an early estimate of the cost-effectiveness of using a point-of-care pharmacogenetic CYP2C19 test in the UK National Health System.' |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
